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Abstract
Background: Degenerative spinal stenosis and instability requiring multilevel spine surgery has been associated
with large blood losses. Factors that affect perioperative blood loss include time of surgery, surgical procedure,
patient height, combined anterior/posterior approaches, number of levels fused, blood salvage techniques, and the
use of anti-fibrinolytic medications. This study was done to evaluate the efficacy of tranexamic acid in reducing
blood loss in spine surgery.
Methods: This retrospective case control study includes 97 patients who had to undergo surgery because of
degenerative lumbar spinal stenosis and instability. All operations included spinal decompression, interbody fusion
and posterior instrumentation (4-5 segments). Forty-six patients received 1 g tranexamic acid intravenous,
preoperative and six hours and twelve hours postoperative; 51 patients without tranexamic acid administration
were evaluated as a control group. Based on the records, the intra- and postoperative blood losses were measured
by evaluating the drainage and cell saver systems 6, 12 and 24 hours post operation. Additionally, hemoglobin
concentration and platelet concentration were reviewed. Furthermore, the number of red cell transfusions given
and complications associated with tranexamic acid were assessed.
Results: The postoperative hemoglobin concentration demonstrated a statistically significant difference with a p
value of 0.0130 showing superiority for tranexamic acid use (tranexamic acid group: 11.08 g/dl, SD: 1.68; control
group: 10.29 g/dl, SD: 1.39). The intraoperative cell saver volume and drainage volume after 24 h demonstrated a
significant difference as well, which indicates a less blood loss in the tranexamic acid group than the control
group. The postoperative drainage volume at12 hours showed no significant differences; nor did the platelet
concentration Allogenic blood transfusion (two red cell units) was needed for eight patients in the tranexamic acid
group and nine in the control group because of postoperative anemia. Complications associated with the
administration of tranexamic acid, e.g. renal failure, deep vein thrombosis or pulmonary embolism did not occur.
Conclusions: This study suggests a less blood loss when administering tranexamic acid in posterior lumbar spine
surgery as demonstrated by the higher postoperative hemoglobin concentration and the less blood loss. But given
the relatively small volume of blood loss in the patients of this study it is underpowered to show a difference in
transfusion rates.
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Degenerative spinal stenosis and instability requiring
multilevel spine surgery can be associated with consider-
able blood loss. The association of increased intra- and
postoperative blood loss during reconstructive spine sur-
gery with higher complication rates has been established
[1,2]. Typical consequences of blood loss are extended
operation times and pulmonary and cerebral edema due
to fluid shifts [2]. As a consequence, blood transfusions
are often required. Yet blood transfusions are not free of
risks, including transfer of infectious agents, increased
risk of postoperative infections and immunological sen-
sitizing including transfusion-related acute lung injury
can occur [3,4]. Measures to decrease transfusion-
related complications such as preoperative autologous
blood donation, application of cell saver-systems or the
use of erythropoietin are often associated with higher
costs and logistic challenges [5-7].
More recently, the use of anti-fibrinolytics has come
into favor for orthopedic surgery. Recent studies have
shown that tranexamic acid is efficient in reducing
blood loss in orthopedic surgery [8-10]. Considering the
risks associated with allogenic blood transfusions, we
aimed in this study to evaluate the efficacy of tranexa-
mic acid in reducing blood loss and the need for allo-
genic blood transfusion in patients undergoing posterior
lumbar spine surgery. Additionally, we observed the
appearance or absence of perioperative complications
that may be associated with the use of tranexamic acid.
Methods
Study Design
Between January 2009 and December 2010, we enrolled
97 patients who were to have a posterior lumbar spine
surgery in this retrospective case control study. All
patients were in need of spinal fusion surgery of 4 to 5
segments owing to degenerative spinal stenosis with
instability. Exclusion criteria were renal dysfunction
identified by a glomerular filtration rate lower than 50
ml/min, current use of anti-coagulant medication, any
history of coronary artery disease with stent placement
and history of thromboembolic events.
The surgery and follow up were performed by the
authors (S.E. and M.H.). All patients underwent fusion
with pedicle screws and rod instrumentation (Tango RS,
Fa. Ulrich, Germany) and intervertebral fusion (PLIF -
Prospace Aesculap, porous titanium). Posterior lumbar
interbody fusion was performed over one to three levels
and in all cases a posterolateral bone graft was done.
The bone graft for fusion (posterolateral fusion) was a
mixture of Endobone
® (Biomet, Germany)and autolo-
gous bone obtained from the decompression procedure.
No iliac crest bone graft harvesting was performed.
Laminectomy, partial resection of the facet and a
foraminotomy were performed on all patients over at
least 3 levels. The average number of posterior instru-
mented levels was 4.8 (range 4-5).
None of the patients had a disease of the coagulation
system, no positive anamnesis of a DVT or a higher risk
o fb l e e d i n g .T h et w os t u d yg r o u p sw e r ec o m p a r a b l ei n
age, weight, height, sex and ASA physical status. The
preoperative coagulation parameters, hemoglobin value
and platelet count were within normal range and
showed no significant differences between groups. The
control group had undergone the lumbar spinal fusion
procedure in 2009 before tranexamic acid use was intro-
duced into our institution an dc o n s i s t e do f5 1p a t i e n t s .
The tranexamic acid group included 46 patients,
enrolled in 2010, who received 1 g tranexamic acid
intravenous preoperative (60 min before surgery) and
six hours and twelve hours postoperative, based on the
study by Zohar et al. [11].
On the basis of the records, the intraoperative (cell
saver drainage volume) and postoperative (self-suction
device) blood losses were measured by evaluating the
drainage and cell saver systems 6, 12 and 24 hours post-
operatively. Cell saver systems were used in all cases.
Additionally, hemoglobin concentration and thrombo-
cyte counts were reviewed. Furthermore, the numbers of
red cell transfusions were assessed, and complications
such as suspected medication or allergic reaction, sus-
pected myocardial infarction, stroke, deep vein thrombo-
sis, pulmonary embolism and renal failure were
analyzed.
Ethical board statement
Approval for the current study was given by the ethical
board of the University of Münster, Germany [AZ 2010-
218-f-s]. This project was performed in accordance with
the Helsinki Declaration and with local legislation.
Statistical Analysis
T h ed a t aw e r ea n a l y z e du s i n gS P S Ss o f t w a r e( v e r s i o n
10.0; SPSS, Chicago, IL). Results are presented as mean
± SD. The independent Student’stt e s tw a su s e dt o
compare the two groups. Differences were considered
significant if the p-value was ≤ 0.05.
Chi quadrat testing was done to compare proportion
between two groups, e.g. ASA classification and surgical
procedures (PLIF and number of segments).
Results
The established practice in our department is that
patients are transfused if postoperative hemoglobin is
< 8 mg/dl in patients with no coronary heart disease,
or < 10 mg/dl in patients who have coronary heart
disease and physiological signs of inadequate
oxygenation.
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mic acid group and 51 in the control group. The tra-
nexamic acid group comprised 31 males and 15 females,
mean age 67 years (SD: 10.5); in the control group there
were 27 males and 24 females with a mean age of 69
years (SD: 9.8). Mean patient weights were 81.98 kg
(SD: 14.53) for the tranexamic acid and 79.78 kg (SD:
13.99) for the control group. The duration of surgery
was 172.74 min (SD: 41.58) for the tranexamic acid
group and 168.09 min (SD: 42.03) for the control group.
A review of the anesthesia records for the patients
showed that 13 patients were of ASA class I, 21 of ASA
class II and 12 of ASA class III in the tranexamic acid
group; and nine were of ASA class I, 16 of ASA class II
and 26 of ASA class III in the control group (Table 1).
The observed intraoperative infused volume (2554.55
ml/SD: 737.26 ml in the tranexamic acid group versus
2433.33 ml/SD: 737.26 ml 782.07 ml in the control
group) and surgical time (172.74 min/SD: 41.85 min in
the tranexamic acid group versus 168.09 min/SD: 42.03
m i ni nt h ec o n t r o lg r o u p )w e r e similar with no statisti-
cally significant differences between the groups.
The mean drop in the postoperative hemoglobin con-
centration was 3.83 g/dl in the tranexamic acid group
and 4.21 g/dl in the control group, a difference of
10.1%. This difference was statistically significant and
showed that the tranexamic acid group was superior
(tranexamic acid group: 11.08 g/dl, SD: 1.68; control
group: 10.29 g/dl, SD: 1.39; (p = 0.013).
The intraoperative cell saver volume (tranexamic acid
group: 470 ml, SD: 153.06; control group: 560 ml, SD:
67.59; p = 0.0002) and the postoperative drainage
volume at 24 hours (tranexamic acid group: 270, SD:
180; control group: 368.75, SD: 211.4; p = 0.0156) also
demonstrated a significant difference which indicates a
less blood loss in the tranexamic acid group than the
control group.
The postoperative drainage volumes at 12 hours
showed no significant differences; nor did the platelet
concentration or complications.
Allogenic blood transfusion (two red cell units) was
given to eight patients in the tranexamic acid group and
to nine patients in the control group because of post-
operative anemia. Intraoperative blood loss was too low
to obtain autologous blood in the cell saver systems.
Therefore no autologous blood transfusions were given
in either group.
No complications associated with the administration
of tranexamic acid occurred, such as suspected medica-
tion or allergic reaction, myocardial infarction, stroke,
renal failure, deep vein thrombosis or pulmonary embo-
lism. Overall results are given in table 2.
Table 1 Demographics
tranexamic acid group SD control group SD p value
Number of patients 46 51
Sex (M/F) 31/15 27/24
Weight (kg) 81.98 14.53 79.78 13.99 0.449
Height (cm) 168.00 6.77 171.35 7.47 0.023
Age 67 10.5 69 9.8 0.334
PTT (s) 27 3.93 26 4.2 0.230
Duration of operation (min) 172.74 41.85 168.09 42.03 0.587
Surgical procedure 0.286
1 segment PLIF 9 17
2 segments PLIF 23 23
3 segments PLIF 12 8
4 segments PLIF 1 3
5 segments PLIF 1 0
Surgical procedure 0.308
1 segment instrumentation 0 0
2 segments instrumentation 0 0
3 segments instrumentation 0 0
4 segments instrumentation 11 8
5 segments instrumentation 35 43
ASA I/II/III 13/21/12 9/16/26 0.042
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Among patients undergoing major orthopedic and spine
surgery, antifibrinolytic agents compared to placebo
reduce bleeding, reduce the risk of transfusion and do
not appear to increase the risk of myocardial infarction,
stroke, deep vein thrombosis or pulmonary embolism
[8,12-19]. These observations are consistent with those
found in the cardiovascular surgery literature [20,21].
The aim of the present study was to evaluate the effi-
cacy of tranexamic acid in reducing blood loss and the
need for allogenic blood transfusion in patients under-
going posterior lumbar spine surgery. Our results suggest
a less blood loss as shown by the higher postoperative
hemoglobin concentration and lower cell saver volume in
the tranexamic acid group. But we found no significant
reduction of allogenic blood transfusion rate with the use
of tranexamic acid. No adverse events with the use of tra-
nexamic acid were seen in our population.
Heterogeneous patient populations (adolescent scolio-
sis, neuromuscular scoliosis, acquired degenerative
instability, etc.), differences in surgical techniques (ante-
rior, posterior, anterior-posterior, lumbar and cervical),
heterogeneity in the doses and type of antifibrinolytic
agent, timing of administration, and a lack of standar-
dized dose regimens and transfusion thresholds may help
to explain why the results of the present study are differ-
ent from those previously published, which showed dif-
ferences in blood loss and transfusion between patients
who received tranexamic acid and those who did not.
Elwatidy et al. reported on the efficacy and safety of a
l a r g ed o s eo ft r a n e x a m i ca c i di ns p i n es u r g e r y[ 9 ] .T h e y
enrolled 64 patients of whom 18 had multilevel anterior
cervical discectomies, 22 had decompressive surgery for
multisegmental stenosis, 15 had laminectomy and posterior
instrumentation and nine had laminectomy and resection
of a spinal tumor. The blood loss during surgery from
patients in TA group was almost half the amount lost from
patients in Placebo group (49% reduction). Consequently
the amount of blood transfusion was 80% less in TA than
in placebo group. The heterogeneity of this study popula-
tion makes it difficult to compare the results because these
procedures entailed more or less significant blood losses.
Another study by Baldus et al. compared the safety
and efficacy of aprotinin and tranexamic acid in control-
ling blood loss during lumbar pedicle subtraction osteot-
omy (PSO) in adults [22]. The main difference from the
present study is that the surgical procedure of PSO is
substantially more complex (duration in the operating
r o o m :7 . 5h o u r sv e r s u s8 . 1h o u r s )a n de n t a i l sg r e a t e r
blood loss (mean 1114 ml - 2260 ml) than decompres-
sive surgery with interbody fusion and instrumentation
Colomnia et al. performed a retrospective case control
study to determine the impact of aprotinin or tranexa-
mic acid use on reducing intraoperative blood loss and
transfusion needs in complex spine surgery. They
enrolled patients with diagnoses of adult scoliosis, neu-
romuscular scoliosis, congenital scoliosis, degenerative
lumbosacral disease and posttraumatic kyphosis. The
surgical procedures varied and included posterior instru-
mented fusion, anterior instrumented fusion, anterior
plus posterior instrumented fusion, posterior lumbar
interbody fusion (PLIF), pedicle subtraction osteotomy
and Smith-Peterson osteotomy. The duration of surgery
was 448 min, the numbers of levels fused 7.6 and the
total blood loss was 1608 ml for tranexamic acid group.
Therefore the total transfusion rate was 2.6. The authors
Table 2 Postoperative data
tranexamic acid group SD control group SD p value
Number of patients 46 51
Hemoglobin (g/dl)
pre operation 14.91 1.1 14.51 1.28 0.103
post operation 1 day 11.08 1.68 10.29 1.39 0.013
mean drop 3.83 0.89 4.21 0.9 0.039
Platelet concentration (tsd/μl)
pre operation 256.75 63.18 268.92 75.71 0.395
post operation 1 day 198.17 57.95 220.71 62.26 0.069
Drainage (ml)
intra operation 470 153.06 560 67.59 0.0002
post operation 6 h 171.25 141.01 258.75 139.8 0.002
post operation 12 h 101.25 72.7 110 131.6 0.69
postop total 24 h 270 180 368.75 211.4 0.016
intraoperative infusions (crystalloids in ml) 2.554.55 737.26 2.433.33 782.07 0.435
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tive factor of total blood loss among the patients [23].
In conclusion, the present authors presume that the
duration of the surgical procedure and type of surgery
are predictive factors for significant blood loss and
transfusion requirement in spine surgery. It is likely that
tranexamic acid use results in a greater reduction in
blood loss and transfusion the longer the surgical proce-
dure lasts and therefore the greater the blood loss is.
Although we conducted a retrospective case-control
study and the possibility of the results being affected by
recall bias due to historical controls cannot be ruled out,
the study provides evidence that the use of tranexamic acid
in posterior lumbar spine surgery is not always necessary.
Given the small volume of blood loss in the patients,
it seems that this study is underpowered to show a dif-
ference in transfusion rates. A much larger sample size
would be necessary to prove this.
But the strengths of this study are the homogenous
patient population in both groups, and the fact that the
surgery was performed by a single surgeon.
Conclusions
On the basis of this retrospective case control study, tra-
nexamic acid use seems not to reduce transfusion rates
in posterior lumbar spine surgery even if less blood loss
was detectable. This could be explained by the lower
bleeding risk and smaller overall blood loss of a poster-
ior approach. Therefore the routine use of tranexamic
acid in posterior spinal surgery has to be carefully con-
sidered to avoid unnecessary complications.
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